Financials

Overview  ·  Financial Reports  ·  Special Reports  ·  SEC Filings  ·  3-year Snapshot  ·  IR Contact

Overview

Mdxhealth operates on a calendar basis with its accounting year ending on Dec. 31. The company reports its consolidated financial statements under International Financial Reporting Standards (IFRS) and all amounts are in US Dollars. Mdxhealth publishes a consolidated and audited Annual Report on an annual basis, a consolidated Interim Report for its June 30 half-year financial figures, and business/financial updates at the end of Q1 and Q3.

Furthermore, for the Annual General Shareholders’ Meeting, the company also publishes the non-consolidated Belgian-GAAP financial statements of the parent company. Prior to October 5, 2010, mdxhealth operated under the name OncoMethylome Sciences.

Financial Reports

Special Reports

The financial service for the shares of the company is provided in Belgium by KBC. Shareholders should inform themselves about the costs that other financial intermediaries may charge in connection with paying agency services.

Edit Content

Auditor Report in relation to capital increase January 26, 2023-contribution in kind (FR)

Auditor Report in relation to capital increase of January 26, 2023 (FR)

Board Report in relation to capital increase of January 26, 2023 (FR)

Board Report in relation to capital increase of January 26, 2023 (EN)

Board Report in relation to the capital increase of August 11, 2022 (ENG)
Board Report in relation to the capital increase of August 11, 2022 (FR)
Auditor Report in relation to the capital increase of August 11, 2022
Board Report in relation to the capital increase of 8 November 2021 (ENG)Board Report in relation to the capital increase of 8 November 2021 (FR)
Auditor Report in relation to the capital increase of 8 November 021 – contribution in kind (FR)
Auditor Report in relation to the capital increase of 8 November 2021 (FR)
Board Report in relation to the capital increase of 26 January 2021 (FR)
Board Report in relation to the capital increase of 26 January 2021 (EN)
Auditor Report in relation to the capital increase of 26 January 2021 (FR)
Report of the Statutory Auditor in relation to the equity investment by MVM, dated May 15, 2020 (EN)
Report of the Statutory Auditor in relation to the equity investment by MVM, dated May 15, 2020 (FR)
Board Report in relation to the equity investment by MVM, dated May 15, 2020 (EN)
Board Report in relation to the equity investment by MVM, dated May 15, 2020 (FR)
Auditor Report I art 596
Auditor Report II art 596
2019-09-Auditors Report art 596
2019-09-EN-Board Report art 596
2019-09-FR-Board Report art 596
2018-03-Auditors Report art 596
2018-03-EN-Board Report art 596
2018-03-FR-Board Report art 596
006 Board Report 596 (FR)[5].pdf
604 Board Report (FR) exec.pdf
604 Board Report (FR).pdf
583 596 598 Board Report and Plan (EN).pdf
583 596 598 Board Report and Plan (FR).pdf
R Mdx art 596-598 Plan d’options sur Action May 2017 – 2.500.000 SOP.pdf
Rapport special du conseil dadministration.article596.Nov_.2016.EN_.pdf
Rapport special du conseil dadministration.article596.Nov_.2016.EN_.pdf(FR).pdf
Rapport du commissaire, article 596, 31 octobre 2006 .pdf
Rapport du conseil d’administration. article 604 avril 2016.pdf
604 Board Report (FR) exec.pdf
Rapport du Commissaire, article 602, 18 septembre 2015.pdf
Rapport du Conseil d’Administration, article 602, 18 septembre 2015.pdf
Report of the Board, article 602, September 18, 2015.pdf
Rapport du commissaire – article 596, 23 juin 2015.pdf
Rapport du conseil d’administration, 23 juin 2015.pdf
Rapport du conseil d’administration, 4 novembre 2014.pdf
Rapport du conseil d’administration – articles 583-596-598 – 30 avril 2014.pdf
Rapport du commissaire – articles 596-598 – 30 avril 2014.pdf
Rapport du commissaire, articles 596 et 598, 24 juin 2013.pdf
Rapport du conseil d’administration, 24 juin 2013.pdf
Rapport du conseil d’administration, article 604, 30 avril 2013.pdf
Rapport du commissaire, articles 596 et 598, 28 juin 2012.pdf
Rapport du conseil d’administration, articles 603 juncto 596 et 598, 28 juin 2012.pdf
Rapport du conseil d’administration, articles 583:596:598, 18 avril 2012.pdf
Rapport du commissaire, articles 596:598, 19 avril 2012.pdf
Rapport du conseil d’administration, articles 583:596:598, 27 mai 2011.pdf
Rapport du commissaire, article 596, 27 mai 2011.pdf
Rapport du commissaire, article 596, 4 avril 2011.pdf
Rapport du conseil d’administration, article 603 juncto l’article 596, 4 avril 2011.pdf
Rapport du commissaire, Art. 582:596:598, 10 mai 2010.pdf
Rapport du conseil d’administration, articles 582:583:596:598, 21 juin 2010.pdf
Rapport du conseil d’administration, article 633, 10 mars 2010.pdf
Rapport du commissaire, article 596, 27 janvier 2009.pdf
Rapport du conseil d’administration, articles 583:596, 27 janvier 2009.pdf
Rapport du commissaire, article 596, 15 décembre 2008.pdf
Rapport du conseil d’administration, articles 603:596:589, 15 décembre 2008.pdf
Rapport du conseil d’administration, articles 583:596:589, 30 mai 2008 .pdf
Rapport du commissaire, article 596, 26 mai 2008.pdf
Rapport du conseil d’administration, articles 604, 27 mars 2008.pdf
Rapport du conseil d’administration, articles 603:596, 15 octobre 2007.pdf
Rapport du commissaire, article 596, 15 octobre 2007 .pdf
Rapport du conseil d’administration, articles 583:596:598, 25 mai 2007 .pdf
Rapport du commissaire, articles 596:598, 21 mai 2007 .pdf
Rapport du conseil d’administration, articles 583:596, 18 avril 2007.pdf
Rapport du commissaire, article 596, 16 avril 2007 .pdf
Rapport du conseil d’administration, articles 583:596, 8 november 2006.pdf

Edit Content

2023 July Prospectus: English l Français

2022 Annual Report: English l Français

2023 January Board Report: English l Français

2023 January Auditor Report Contribution in Kind: Français 

2023 January Auditor Report: Français

 

For the press releases incorporated by reference to this Listing Prospectus, please see: Press Releases

Edit Content

2021 December Prospectus: English l Français

2021 Interim Report: English l Français

2020 Annual Report: English l Français

2021 November Board Report: English l Français

2021 November Auditor Report: Français

2021 November Auditor Report Contribution-in-Kind: Français

For the press releases incorporated by reference to this Listing Prospectus, please see: Press Releases

Edit Content

2021 Prospectus: English I Français

2020 Interim Report: English I Français

2019 Annual Report: English I Français

2021 Board Report: English I Français

2021 Auditor report in relation to the capital increase of 26 January: Français

2020 FY Unauditied Consolidated Financial Statements: English

Edit Content

2019 Annual Report: English I Français

2020 H1 Interim Report: English I Français

2020 Board Report: English I Français

2020 Report on Statutory Auditor in relation to the equity investment by MVM: English I Français

2020 Prospectus: English I French

Edit Content

2015 Summary Note: English | Francais

2015 Securities Note: English | Francais

2014 Registration Document: English | Francais

Edit Content

2013 Summary Note: English | Francais

2013 Transaction Note: English | Francais 

2012 Registration Document: English | Francais

Edit Content

2011 Registration Document: English | Francais

Securities Transaction Note – July 4, 2012: English | Francais

Summary Note – July 4: English | Francais

Edit Content

2010 Registration Document: English | Francais

Securities Transactions Note -April 7, 2011: English | Francais

Summary Note – April 7, 2011: English

SEC Filings

3-year snapshot

In “000” of USD

Edit Content

Edit Content

Edit Content

Edit Content

Investor Relations Contact

For all investor related questions please call or email:

LifeSci Advisor (PR & IR)

US: +1.949.271.9223
ir@mdxhealth.com

Toll Free: (866) 259-5644
Email: info@mdxhealth.com
Facebook Twitter Linkedin
Our Company
Tests

For Physicians

For Patients

Investors